Intestinal Cancer: Understanding Colorectal and Small Intestine Cancers

The intestines — comprising the small intestine and the large intestine (colon) and rectum — form the central channel of the body's digestive system. When cancer develops in these tissues, it can disrupt all of these functions and, if not caught early, spread to other parts of the body with serious consequences.

"Intestinal cancer" broadly refers to malignancies arising in the intestinal tract. The two most clinically significant categories are colorectal cancer (affecting the colon and rectum) and small intestine cancer (rarer but increasingly recognized).

"Colorectal cancer is the second most common cause of cancer death in the United States — and now ranks first in cancer-related deaths among adults younger than 50." — CA: A Cancer Journal for Clinicians, Colorectal Cancer Statistics 2026

The Scale of Intestinal Cancers in America (2026)

• 158,850 Americans expected to be diagnosed with colorectal cancer in 2026
• 55,230 projected colorectal cancer deaths in 2026
• 14,450 new small intestine cancer cases expected in 2026
• +3%/year rise in colorectal cancer rates among adults aged 20–49 (2013–2022)

Colorectal Cancer vs. Small Intestine Cancer

While both originate in the intestinal tract, colorectal cancer and small intestine cancer differ significantly in prevalence, biology, risk factors, and how they are detected and treated.

Colorectal Cancer (colon & rectum): The 4th most common cancer in the U.S. Overall incidence has declined 45% since 1985 — but is rising sharply in younger adults. Highly preventable and treatable when caught early through routine screening. Colonoscopy can find and remove precancerous polyps before cancer develops.

Small Intestine Cancer (duodenum, jejunum, ileum): One of the rarest GI cancers despite the small intestine being the longest segment of the digestive tract. Often diagnosed late due to vague or absent early symptoms. No standard screening test exists. Incidence has been rising slowly over decades.

Types of Intestinal Cancer

Adenocarcinoma — Accounts for over 95% of colorectal cancers and about 30–40% of small intestine cancers. Starts in the gland cells lining the inside of the intestine. Most begin as benign polyps that can be detected and removed before becoming cancerous.

Carcinoid / Neuroendocrine tumors (NETs) — The most common type of small intestine tumor overall. Typically slow-growing but can spread to the liver. May cause "carcinoid syndrome" — flushing, diarrhea, and wheezing — when they metastasize.

Lymphoma — Cancer of the immune cells in the intestinal wall. More common in the small intestine than the colon. Strongly associated with celiac disease, Crohn's disease, and immunocompromised states.

Gastrointestinal stromal tumor (GIST) — A type of sarcoma arising from the connective tissue of the GI tract. Often driven by a specific gene mutation (KIT or PDGFRA). Targeted therapy with imatinib has transformed treatment outcomes.

Mucinous adenocarcinoma — A variant of colorectal adenocarcinoma that produces large amounts of mucus. Accounts for about 10–15% of CRCs. Associated with Lynch syndrome.

Signet ring cell carcinoma — A rare, aggressive form of adenocarcinoma associated with poor prognosis due to early spread and resistance to standard chemotherapy.

Risk Factors for Intestinal Cancers

Age — Risk increases significantly with age. Most colorectal cancers are diagnosed in adults over 50 — though rates in those under 50 are rising rapidly.

Personal or family history — A first-degree relative with colorectal cancer substantially raises risk. Genetic syndromes including Lynch syndrome and familial adenomatous polyposis (FAP) account for up to 10% of colorectal cancers.

Inflammatory bowel disease (IBD) — Crohn's disease and ulcerative colitis are associated with increased risk of both colorectal and small intestine cancer.

Diet high in red and processed meat — Consistently linked to higher colorectal cancer risk. A diet rich in fiber, fruits, and vegetables is protective.

Physical inactivity and obesity — Sedentary lifestyle and excess body weight are independent risk factors, with obesity linked to more aggressive disease.

Smoking and heavy alcohol use — Both are associated with increased colorectal cancer risk.

Type 2 diabetes — People with type 2 diabetes have a higher risk of colorectal cancer, possibly due to elevated insulin levels.

Celiac disease — Long-standing untreated celiac disease is associated with significantly increased risk of small intestine lymphoma and adenocarcinoma.

A striking trend: from 2013 to 2022, colorectal cancer incidence increased by 3% annually in adults aged 20–49. CRC is now the leading cause of cancer death in Americans under 50.

Symptoms of Intestinal Cancer

Early-stage intestinal cancer often produces no symptoms — which is precisely why routine screening matters. When symptoms do appear, they are frequently nonspecific.

Colorectal cancer symptoms: Blood in the stool or rectal bleeding; change in bowel habits lasting more than a few weeks; persistent abdominal pain or cramping; feeling that the bowel doesn't empty completely; unexplained weight loss; fatigue or weakness; unexplained iron-deficiency anemia; narrow or pencil-thin stools.

Small intestine cancer symptoms: Abdominal pain or cramping; nausea and vomiting; unexplained weight loss; dark or tarry stools (GI bleeding); jaundice (yellowing of skin or eyes); fatigue and weakness; flushing or diarrhea (carcinoid syndrome); bowel obstruction in severe cases.

Never assume rectal bleeding is "just hemorrhoids" without medical evaluation — especially if you are 40 or older or have a family history of colorectal cancer.

Colorectal Cancer Screening — It Saves Lives

Colorectal cancer is one of the few cancers that can be prevented, not just detected early. The overall colorectal cancer death rate has dropped by more than 1.5% per year in older adults over the past decade — largely due to increased screening and polyp removal.

When to start: The American Cancer Society recommends that people at average risk begin regular colorectal cancer screening at age 45. Those with a family history should discuss starting earlier.

Colonoscopy — The gold standard. A flexible scope examines the entire colon and rectum; polyps can be removed during the same procedure. Recommended every 10 years if results are normal.

Stool-based tests — Non-invasive home options include the fecal immunochemical test (FIT, annually), the guaiac-based FOBT (annually), and the multi-target stool DNA test (Cologuard, every 1–3 years). Positive results must be followed up with colonoscopy.

CT colonography (virtual colonoscopy) — A CT scan creates detailed images of the colon every 5 years. Requires bowel prep, and any polyps found require follow-up colonoscopy.

Survival Rates by Stage

Stage at diagnosis is the single most powerful predictor of outcomes:

• Localized (confined to bowel wall): 91% 5-year survival
• Regional (spread to nearby lymph nodes): 72% 5-year survival
• Distant (metastasized): 18% 5-year survival
• Overall (all stages): 65% 5-year survival

Treatment Options

Surgery — The primary treatment for most localized cancers. Involves removal of the cancerous segment and nearby lymph nodes. Minimally invasive laparoscopic approaches have reduced recovery time significantly.

Chemotherapy — Used after surgery to reduce recurrence risk, or as primary treatment for metastatic disease. Common regimens include FOLFOX and CAPOX for colorectal cancer.

Radiation therapy — Particularly used for rectal cancer before surgery to shrink tumors, or after surgery to reduce local recurrence.

Targeted therapy — Drugs attacking specific molecular targets in cancer cells. Bevacizumab, cetuximab, and panitumumab are used in metastatic colorectal cancer. Imatinib is the cornerstone of GIST treatment.

Immunotherapy — Checkpoint inhibitors such as pembrolizumab are now first-line treatment for metastatic colorectal cancers with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). Molecular testing at diagnosis is essential.

Somatostatin analogs (for NETs) — Medications like octreotide and lanreotide can control hormone-related symptoms and slow tumor growth in carcinoid/neuroendocrine tumors.

Don't Wait for Symptoms — Screen Before They Appear

Colorectal cancer is one of the most detectable and preventable cancers in existence — when people show up for screening. If you are 45 or older — or younger with risk factors — talk to your doctor about which screening option is right for you.

iHealth Network's doctor directory connects you with gastroenterologists, colorectal surgeons, and oncologists near you. Our clinical trials resource is a gateway to the latest research in intestinal cancer treatment.

This article is for informational purposes only and does not constitute medical advice. Sources: American Cancer Society Cancer Facts & Figures 2026; CA: A Cancer Journal for Clinicians — Colorectal Cancer Statistics 2026; Colorectal Cancer Alliance; WHO Colorectal Cancer Fact Sheet (February 2026).